Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20639342 | 1.00 | SCN10A (0.38) | SCN10AMPOKMT2A | |
| SCHEMBL238095 | 0.93 | SCN10A (0.38) | SCN10A | |
| SCHEMBL15452940 | 0.93 | SCN10A (0.38) | SCN10A | |
| SCHEMBL2278873 | 0.93 | SCN10A (0.38) | SCN10A | |
| SCHEMBL241229 | 0.92 | SCN10A (0.38) | SCN10AMPO | |
| SCHEMBL239849 | 0.90 | SCN10A (0.36) | SCN10AKMT2A | |
| SCHEMBL20694958 | 0.90 | SCN10A (0.43) | SCN10AMPO | |
| SCHEMBL241559 | 0.90 | SCN10A (0.43) | SCN10AMPO | |
| SCHEMBL239572 | 0.88 | SCN10A (0.41) | SCN10A | |
| SCHEMBL242113 | 0.88 | SCN10A (0.41) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | claimed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | claimed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-20210171506-A1 | Process for Manufacturing Pibrentasvir Active Drug Substance | ABBVIE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| US-20210171506-A1 | Process for Manufacturing Pibrentasvir Active Drug Substance | ABBVIE INC. (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112638368-A | Process for the manufacture of piretavir active pharmaceutical substance | 艾伯维公司 | 2021-04-09 | — | — | CN | disclosed |
| WO-2020047182-A1 | PROCESS FOR MANUFACTURING PIBRENTASVIR ACTIVE DRUG SUBSTANCE | ABBVIE INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| EP-2692346-B1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | ABBVIE BAHAMAS LTD (BS) | 2015-12-02 | — | — | EP | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2692346-A1 | An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| EP-2692726-A1 | Anti-viral compounds | Abbvie Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110207699-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20150087618-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20110207699-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20210171506-A1 | Process for Manufacturing Pibrentasvir Active Drug Substance | CYP3A5, CYP3A4, HAVCR2 | SCN10A 4397/4885MPO 3910/4885KMT2A 2672/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | SCN10A 4583/4885MPO 762/4885KMT2A 4093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.